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ABSTRACT 
Cytotoxic lymphocytes encompass natural killer (NK) cells and cytotoxic T lymphocytes (CTL). 
These cells detect and kill virus-infected as well as malignant cells. Primary defects in 
lymphocyte cytotoxicity are associated with development of a hyperinflammatory syndrome 
termed hemophagocytic lymphohistiocytosis (HLH). This thesis investigates cytotoxic 
lymphocyte function in HLH cases as well as the creation of new assays to improve diagnostics.  
An NK cell degranulation assay has been developed to quantify NK cell responses as an 
alternative to the radioactive chromium release assay. CD107a is a transmembrane protein that in 
unstimulated cells is contained within the inner membrane of perforin-containing cytotoxic 
granules but is exposed on the cell surface upon cytotoxic granule exocytosis. In a pan-European 
effort, we established and validated a consensus protocol for the diagnosis of primary HLH 
patients with defective degranulation (Paper II). NK cell degranulation below 5% predicted a 
primary defect in exocytosis leading to defective lymphocyte cytotoxicity with 96% sensitivity 
and 88% specificity. We also provided further optimized protocols for NK cell phenotyping and 
degranulation (Paper I).  
Highlighting the importance of reliable functional assays in primary immunodeficiency 
discovery, we described novel non-coding aberrations in UNC13D as a cause of HLH and 
defective degranulation (Paper III, IV). Point mutations were found in a highly conserved 
intronic region, while a 253kb inversion was identified as the most frequent cause of HLH in 
Swedish infants. 
ORAI1 and STIM1 mediate store-operated Ca2+ entry in T cells, which is required for induction 
of cytokine expression. However, the role of store-operated Ca2+ entry was not clear. In Paper V, 
we studied NK cell cytotoxicity using ORAI1 and STIM1-deficient patients, confirming 
abrogated Ca2+ entry upon target cell stimulation. Importantly, ORAI1 and STIM1-deficient NK 
cells did not degranulate nor produced proinflammatory cytokines, demonstrating that store-
operated Ca2+ entry is required for overall cytotoxic lymphocyte effector functions.   
Primary HLH diagnostics have relied on NK cell functional assays but little had been done to 
evaluate T cell responses in these patients. In Paper VI, we described how the surface marker 
CD57 can be used to identify bone fide cytotoxic T lymphocytes, readily allowing identification 
of a T cell subset that expresses intracellular perforin and can efficiently kill target cells upon 
TCR engagement. The CD8+CD57+ T cell subset, similar to CD56dim NK cells, was found to 
display defective degranulation in FHL types 3-5, suggesting CTL and NK cell exocytosis has 
similar molecular requirements. In paper VII, we compared the established K562 cell-induced 
NK cell degranulation assay (Paper II) against the newly developed T cell degranulation assay 
(Paper VI) prospectively evaluating all primary immunodeficiency patients sent to our laboratory 
during a 3 year period. The T cell assay excelled with respect to sensitivity and specificity (97% 
and 95%, respectively) for predicting a primary defect in degranulation. Combining NK cell and 
T cell assays further increased assay specificity.  
This thesis demonstrates the power of functional assays in evaluating cytotoxic lymphocyte 
activity and how this expands our understanding of their biological role and the primary HLH 
syndrome. These simple, rapid and accurate assays give us the power to quickly diagnose a life-
threatening disease and initiate treatment, thus saving lives.  
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1 INTRODUCTION  
Blood acts as a transporter and regulator for many crucial systems in the body including 
respiration, osmosis, heat transfer, nutrition, waste removal, regulatory molecules, clotting 
factors, and the circulating immune system. White blood cells, or leukocytes, are part of the 
immune system in blood and have continually been divided into smaller and smaller subsets 
as science races to discover novel functions for each new population. Broadly, leukocytes can 
be partitioned into polymorphonuclear cells, monocytes, and lymphocytes. 
Polymorphonuclear cells make up the largest leukocyte subpopulation and recognize 
disrupted, opsonized, or cells expressing pathogen-associated molecular patterns (PAMPs) 
(1). This group is made up of neutrophils that respond by engulfing pathogens, basophils that 
excrete histamines, enzymes, and cytokines, and, eosinophils that produce reactive oxygen 
species as well as cytokines. Monocytes react to an infection by migrating to the site of injury 
where they differentiate into macrophages and dendritic cells. These are then named 
professional antigen presenting cells and function by engulfing and presenting foreign 
antigens on their surface. Dendritic cell can migrate to the lymph node in order to activate T 
cells, while macrophages efficiently clear off cell debris and dying cells. Besides functioning 
as a specialized phagocyte, macrophages can also kill target cells via antibody dependent 
cell-mediated cytotoxicity (2), and release cytokines (3).  
The lymphocyte population consists of adaptive B cells and T cells that undergo RAG-
dependent recombination of antigen receptors, as well as RAG-independent innate lymphoid 
cells (4). Upon recognition of an antigen through the B cell receptor, naïve B cells mature and 
produce specific antibodies against the recognized antigen and undergo somatic 
hypermutation to improve target recognition. Long-lived memory B cells can lay dormant 
until a secondary response is called for. T cells specifically recognize foreign protein antigens 
in the context of MHC, and will similarly expand and produce memory cells before the 
immune response is terminated by feedback mechanisms such as CTLA4 (5), or other 
regulatory cells, such as NK cells (6), leading to clonal contraction. Innate lymphoid cells 
(ILC) are lineage negative cells that are further categorized based on surface receptors and 
secreted cytokines. NK cells are the only subtype in ILC with cytotoxic potential (4) while 
other ILC groups are involved in the formation of secondary lymphoid organs, 
immunoregulation, and immunity against intracellular bacteria, parasites, and helminths.  
The human body has a wide range of defenses to protect itself against the multitude of 
pathogens in the environment. With recent advancements and studies on patients with 
specific defects in their defense system, we are becoming more aware of the intricate 
overlapping function and inter-dependence between various members keeping us disease 
free. 
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1.1 NK cells 
NK cell activity was first identified as a lymphocyte subset that could kill tumor cells without 
any prior sensitization (7). Their activity has later also been associated with control of virus 
infected and transformed cells (8-11). Because NK cells are in such an ‘armed and ready to 
kill’ state, strict controls over their function is necessary (12). Later, the observation that NK 
cells kill MHC class I deficient tumor cells (13) led to the ‘missing self’ hypothesis (14). 
Polymorphic inhibitory Ly49A and KIR Ig-like receptors were later identified on mice and 
human NK cells, respectively, thereby molecularly explaining “missing self” (15,16). 
Following which NKG2A was identified in both human and mice (17). All these inhibitory 
receptors bind MHC class I, inhibiting NK cell function. However, NK cell activation is not a 
default setting. Cellular activation requires specific signals from activating neceptors. A 
myriad of receptors with a capacity to activate NK cells have been identified. Some NK cell 
activating receptors bind ligands on activated immune cells, facilitating NK cell killing of 
activated macrophages and T cells (18). NK cells thereby play an important 
immunomodulatory role, attenuating immune cells once an infection has been cleared to 
minimize bystander damage. Moreover, reports on defective NK cells in cancer cohorts (19) 
and the proven usefulness in harnessing NK cells for cancer therapy (20) points to the fact 
that NK cells are important player in control of cancer. Not least, NK cells also produce large 
amounts of cytokines and chemokines, especially IFN-γ and TNF-α for recruiting other 
immune cells to the site of infection as well as to activate other cells in the vicinity (21).  
NK cells express a range of activation receptors. CD16 is a low affinity receptor for Fc 
expressed on NK cells, thus facilitating activation towards antibody coated target cells. Other 
NK cell stimulating receptors include activating KIRs, NKp30, NKp46, NKG2C, NKG2D, 
DNAM-1, and 2B4. Some require co-stimulation to initiate NK cytotoxicity. NKG2D and 
2B4 for example, when stimulated together leads to a synergistic effect with high percentages 
of NK cell that degranulate, kill target cells, and secrete cytokines (22). However, when either 
receptor is activated alone, poor responses are generated. 
NK cells are traditionally categorized as part of the innate system because they have 
preformed defense mechanisms in place before an infection occurs and because NK cells 
respond in essentially the same way to repeated infections (23). It has been however pointed 
out that the maximal potential for NK cell killing is only realized after ‘priming’ via 
cytokines (24), and while NK cells rely on germline encoded receptors that do not undergo 
somatic recombination, there is a high individual variability in the number and combination 
of KIR receptors (25). NK cells are also able to clonally expand (26) and very recently were 
shown to display memory-like features in primates (27). Both arms of the immune system are 
however deeply intertwined. The innate system controls most infections well and holds out 
until the adaptive cells have had time to clonally expand and mature. Once an infection has 
been cleared, NK cells help regulate other activated cells (28,29). Another possible route NK 
cells could take in order to perform such varied tasks is through reprograming at the 
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epigenetic level (30,S.XI). As such, NK cells occupy a unique niche by having features of 
innate immunity but showing traits of adaptability and memory (24).  
 
1.2 T cells 
T cells represent the largest lymphocyte subpopulation and require a maturation step in the 
thymus giving them their name. A result of somatic recombination generating a vast diversity 
of unique, clonally distributed receptors, the T cell receptor (TCR) is the main activating 
receptor, and works alongside a few co-receptors. Naïve T cells receiving a signal through 
both TCR and a co-receptor would divide and be activated to produce cytotoxic proteins 
while cells that only receive the TCR signal may undergo anergy (23). T cells can be 
generally divided into two fractions: CD4 and CD8. CD4 T-helper cells function as regulators 
and exert their effect through collaboration with other immune cells namely B cells to 
proliferate and differentiate, and macrophages to break down phagocytized microbes. CD4 
cells also release cytokines that help regulate other immune cells.  
CD8 cytotoxic T lymphocytes (CTL) can exert cytotoxic responses. The CTL compartment 
together with NK cells are known as cytotoxic lymphocytes (CL), and are involved in cell-
mediated immunity. CTLs control intracellular microbes by recognizing non-self peptides 
attached to MHC I on cell surfaces and immediately targets them (31). Should MHC I be 
downregulated to escape T cell detection as in the case of many cancers (32), NK cells will 
instead be sensitized. Once the infection is controlled, a subset of memory T cells will persist 
and produce a more rapid and efficient response upon a repeat intrusion of the same 
pathogen.  
The immune system is thus highly complex and regulated. NK and T cells occupy separate 
niches in cellular immunity and play complimentary roles. Generally, our immune system 
protects against threats from the outside but in some persons, a defect inside the genetic code 
disrupts this delicate balance. Those bearing a deficiency or overactivation of a particular 
immune component could present with a wide range of symptoms. Less severe errors might 
be undetected due to redundancy of the immune system, while at the other end of the 
spectrum severe alterations could lead to death.  
 
1.3 Primary immunodeficiencies 
Primary immunodeficiencies (PID) are diseases caused by inborn errors in genes required for 
immune function. Genetic replication and repair is inherently imperfect, with errors either 
leading to a better adapted species, or more commonly being detrimental and leading to 
disease. The first article describing a possible PID is attributed to a German publication in 
1922 where a group of patients presenting with severe neutropenia was reported (33). Then in 
1952, Bruton described a male patient who had suffered 18 episodes of pneumonia and later 
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found to totally lack gammaglobulin. The patient was administered gammaglobulin injections 
and responded well (34).  
There are more than 250 described PIDs today (35). These have been divided into various 
categories including combined immunodeficiency, defects in innate immunity, antibody 
deficiency, complement deficiency, and immune dysregulation. Estimating the PID 
population incidence rate worldwide is difficult as there is a large variability in the level of 
healthcare facilities and reporting, an ever increasing number of new genes implicated in PID, 
specific endemic mutations in particular geographical gene pools, and differing social 
practices e.g. consanguinity (36,37). An extrapolation estimated that up to six million people 
worldwide live with a PID with just 0.6% of these diagnosed (38). Data on the number of 
diagnosed persons in various countries however are sparse and vary tremendously per 100000 
living inhabitants, with 83 in USA (39), 19 in Iceland (40), 4.6 in Australia and New Zealand 
(41), 2.3 in Japan (42), and 1.5 in Germany (43).  
Many PIDs are passed down through Mendelian inheritance patterns, i.e. autosomal recessive 
but other forms do exist including dominant negative (44), hemizygous (X-linked) (45), 
hypomorphic (46), and gain of function (47) mutations. In this thesis, we focus on a particular 
family of PIDs and its specific effect on CL function. Rare individuals have been found with 
NK cells that fail to kill MHC class I deficient cells or opsonized targets. These patients may 
carry mutations in one of the genes involved in the synthesis of lytic granule content, the 
transport of lytic granules to the cell surface, or the release of lytic granule content towards 
the target cell (48).  
 
1.4 Hemophagocytic lymphohistiocytosis 
Hemophagocytic lymphohistiocytosis (HLH) is a disease of immune dysregulation, 
according to the International Union of Immunological Societies classification (35). This 
condition is currently recognized by a molecular diagnosis or the fulfillment of at least 5 out 
of 8 of the criteria presented in Table 1 (49-51). Although named ‘hemophagocytic’, the 
detection of hemophagocytosis which entails the excessive engulfment of cells by activated 
macrophages usually only comes late in disease progression (52). In fact, criteria 1 through 7 
can be found individually in other diseases (53-58). Hence, it is suggested that the HLH 
acronym be renamed “hyperinflammatory lymphohistiocytosis” (59). When first suggested, 
only the first five criteria were listed and fulfilling all five was required for diagnosis (50). 
This underscores the severity and unique disease clinical pattern (60). HLH is usually incited 
by an infection or malignancy. Macrophages and other leukocytes are activated to clear the 
non-self antigens but due to an ineffective immune response, there is an overproduction of 
inflammatory cytokines and expansion of T cells but no disease resolution (61). Thus, 
activated histiocytes, including macrophages, are activated and can be found accumulated in 
various organs. One obvious reason why this happens is because of malfunctioning CL. As 
would be expound on, low or absent CL function could be used as an accurate diagnosis of a 
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group of primary HLH, as confirmed by molecular results, and represents the only 
pathognomonic criteria in Table 1. 
 
Table 1. Diagnostic guidelines for HLH from the HLH-2004 protocol. 
 
 
 
 
 
 
 
 
 
At the point of the HLH-2004 publication (49), as it still is today, the method of choice for 
analyzing cytotoxic cell killing activity is the chromium release assay. First published from 
Karolinska in 1965 (62) and refined over the years (63,64), it has remained the widely 
accepted ‘gold standard’ for assessing CL killing although no systematic study on the 
sensitivity and specificity of the chromium release assay in discriminating HLH cases has 
been published. As early as 1977, patients with HLH were found to be deficient in 
lymphocyte killing via the chromium release assay (65). Later on, sporadic reports found 
absent NK degranulation in primary HLH cases via flow cytometry (66-70). This new assay 
analyzed effector cell response, unlike the chromium assay where target cell lysis was 
measured. However, there is no consolidated effort to study large cohorts of primary HLH 
and neither was there a consensus protocol on performing NK degranulation assays. What 
was then needed was a study to thoroughly evaluate NK cell degranulation for the diagnosis 
of primary HLH.  
 
1.4.1 Primary HLH 
HLH is traditionally divided into two groups: primary and secondary (71). Primary HLH, 
also known as familial HLH (FHL) represents patients with an inherited autosomal recessive 
deficiency in genes of which many are associated with defective lymphocyte cytotoxicity 
(Table 2). When manifest but left untreated, the disease would ultimately lead to death (65). 
Secondary or sporadic cases on the other hand are thought to be incidental occurrences 
1. Unremitting fever  
2. Splenomegaly  
3. Cytopenias (affecting ≥2 of 3 lineages in the peripheral blood):  
• Hemoglobin <90 g/L 
• Platelets <100 x 109/L  
• Neutrophils <1.0 x 109/L  
4. Hypertriglyceridemia and/or hypofibrinogenemia:  
• Fasting triglycerides ≥3.0 mmol/L (i.e., ≥265 mg/dl)  
• Fibrinogen ≤1.5 g/L  
5. Hemophagocytosis in bone marrow or spleen or lymph nodes  
6. Ferritin ≥500 mg/L  
7. Soluble CD25 (i.e., soluble IL-2 receptor) ≥2,400 U/ml 
8. Low or absent NK-cell activity (according to local laboratory reference)  
No evidence of malignancy  
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secondary to a primary malignant, infectious, autoimmune disease, or complications due to 
therapy, with no clear genetic determinant established (72). This taxonomy is important as 
current treatment varies between the two groups. Hematopoietic stem cell transplantation 
(HSCT) is for the moment the only curative treatment for primary HLH. This is performed 
according to the HLH-94 protocol based on chemotherapy and immunotherapy followed by 
transplantation (51,73). Although transplantation is associated with considerable risks, a 
delay increases the chance of neurological symptoms in primary HLH patients (74). For 
secondary cases however, patients undergo cytotoxic and immunomodulatory treatment but 
would not normally proceed with HSCT as most remain disease free after initial treatment 
(75,76). As such, there is a need for rapid, sensitive, and simple assays for the differentiation 
of these two subgroups as patient counseling becomes simpler once a diagnosis is achieved. 
Taking this one step forward, patients found with defective NK cell function can be evaluated 
for genetic alterations. This could be one route for the discovery of new mutations leading to 
defective degranulation. 
The first familial HLH case report was published in 1952 (77), but only in 1996 was the LYST 
gene, linked to Chediak-Higashi syndrome identified (78). Then in early 1999, perforin and 
the associated apoptotic components were suggested to be involved in familial HLH (79). 
This was quickly followed that same year by a seminal paper describing perforin gene defects 
in familial HLH cases (80). A few years on, other familial HLH patients with defects in 
UNC13D, STX11, STXBP2, RAB27A, and AP3B1 were described in quick succession (Table 
2) (68,81-86). Long before the identification of these genes, CL abnormalities were already 
reported in HLH patients and suggested to be the cause of disease (65,87,88). To note, those 
harboring defects in RAB27A, LYST, and AP3B1 almost always display partial albinism as 
these genes are involved in melanin storage and transport (89,90). Care should be taken when 
evaluating patients of Caucasian background as fair skin could mask the underlying albinism 
(91).  
With time, although primary HLH is a rare disease with an estimated incidence rate of 
1.2:1,000,000 in Swedish children <15 yo (92,93), or 1.07:10,000 children in Texas (94), 
hundreds of primary HLH cases have been documented. Amongst these, reports of patients 
succumbing to HLH with monoallelic mutations or multiple heterozygous mutations in 
different primary HLH genes are raising questions on the inheritance pattern of primary HLH 
as well as the environmental factors leading to disease (95-99). Monoallelic mutations in 
primary HLH genes are also being linked with cancer (100,101). It remains to be proven if 
monoallelic mutations in HLH genes do in fact lead to disease or there exists mutations on 
the second allele that are not picked up with regular sequencing. Alternatively in these 
patients, there is a possibility that yet to be described gene(s) linked to HLH are defective. 
Additionally, are other carrier relatives healthy, especially the parents?  
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Table 2. List of major PIDs studied in this thesis. 
Gene Protein Syndrome OMIM 
PRF1 Perforin FHL2 170280 
UNC13D Munc13-4 FHL3 608898 
STX11 Syntaxin 11 FHL4 605014 
STXBP2 Munc18-2 FHL5 613101 
AP3B1 AP-3 complex subunit  
beta-1 
HPS2, Hermansky-Pudlak  
syndrome 2 
608233 
RAB27A Rab27a GS2, Griscelli syndrome  
type 2 
607624 
LYST Lysosomal-trafficking  
regulator 
CHS, Chediak-Higashi  
syndrome 
214500 
SH2D1A SAP XLP1 308240 
XIAP XIAP XLP2 300635 
ORAI1 CRAC channel protein 1 IMD9 610277 
STIM1 Stromal interaction 
molecule 1 
IMD10 612783 
 
Patients fulfilling HLH criteria but displaying normal CL function have also been 
documented including ITK (102), CD27 (103), GATA2 (104), BIRC4 (105,106), and SH2D1A 
deficiency (107). As such, ‘low or absent NK cell activity’ cannot be used as one of the 
diagnostic guidelines for these primary HLH cases. Moreover, new diagnostic assays need to 
be designed (108-111) and the HLH nomenclature clarified. 
While patient evaluation has focused on NK cells from primary HLH cases, few have worked 
on patient CTL (112) as they generally require a long stimulation and clonal expansion step 
before gaining cytotoxic potential. Mice studies have recognized the different roles played by 
NK and CTL in maintaining immune homeostasis (12,113). It is thus of interest to evaluate 
both arms of the CL in primary HLH patients. We addressed this issue by designing a T cell 
degranulation assay to evaluate cytotoxic T cell function without requiring any prior 
activation. By juxtaposing the established NK assay against this T cell degranulation assay, 
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we hope to draw conclusions on the similarities between these two arms of CL and improve 
diagnostics. 
 
1.4.2 Secondary HLH 
Great strides have been made in the understanding and diagnosis of primary HLH. However, 
it has been more challenging to study secondary HLH. Also known as adult onset or sporadic 
HLH, searching Pubmed would return case reports of patients with very varied diseases 
fulfilling HLH criteira. This includes spider bites (114), inborn errors of metabolism (115), 
Gaucher’s disease (116), rheumatic diseases (117), macrophage activation syndrome (118), 
malignancy (119), dengue virus (120), Ebola virus (121), HIV (122), leishmania (123), Lyme 
disease (124), leprosy (125), tuberculosis (126), and various other zoonoses (127). 
Large overlaps in clinical features and genes involved in primary and secondary HLH have 
blurred the distinction between those two groups. Primary defects lead to increased 
susceptibility to infections for example EBV in X-linked lymphoproliferative diseases (128-
130). Thus, seemingly secondary cases could in fact be due to a primary cause. As DNA in 
every person contains unique variations, minor changes in one or several genes could lead to 
increased disease susceptibility given the right environmental factor or pathogen. It has been 
suggested that everyone has at least one mutation affecting the immune system (131). 
However, it is almost never detected as a very specific antigen needs to be encountered and 
the high immune redundancy normally compensates for the deficiency. Studying intronic 
mutations, regulatory elements, epigenetic changes, multiple gene effects, and somatic 
mutations would feature in the next generation of PID research but would require exponential 
effort to fully comprehend.  
There have been efforts made to differentiate primary HLH, secondary HLH, and other 
hyperinflammatory diseases using laboratory parameters. Adult HLH cases were found to 
have skewed CD3 populations (132) while ferritin levels are distinguishable between primary 
HLH and virus-associated HLH (133). In an intensive care unit setting, it was possible to 
differentiate HLH cases solely based on ferritin levels (134). Another study found the soluble 
IL2 receptor/ferritin ratio a good marker to differentiate pediatric primary HLH from other 
pediatric hemophagocytosis fulfilling HLH criteria (135). Thus, noticeable differences can be 
found between these syndromes giving us reason to believe there are unique genetic or 
environmental backgrounds in the various groups of diseases. However, the disease spectrum 
of HLH is more continuous rather than discrete (136) and vast overlaps between what is 
currently known as primary and secondary HLH could confound efforts. Still, there is a need 
to develop more sensitive functional assays and genetic screenings to try to tweeze apart 
these closely related phenotypes.   
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1.5 HLH Therapy 
Patients with primary HLH will, as a first-line treatment, be subject to intense 
immunosuppression and anti cytotoxic drugs. This is to suppress the underlying life 
threatening inflammation (51). After the initial therapy, immunosuppressive drugs will be 
administered to maintain the patient in a stable resolution of disease and be ready for HSCT 
when a donor becomes available. For secondary HLH, only anti inflammatory or 
immunosuppressive drugs would be prescribed (75). In 1983 where specific HLH therapy 
was non-existent, only 3% of patients with HLH survived long term (65). This improved to 
55% long term survival with the HLH-94 protocol (137) which is the current standard of care, 
confirmed in an independent retrospective report (94). 
In an effort to reduce patient mortality in the pre-transplant phase as well as the high levels of 
central nervous system complications, various studies have considered other drugs and 
combinations (49,138,139). Many patients bear infections at pre-transplant or are susceptible 
to infections because of the immunodeficiency they carry. Reduced intensity conditioning 
would hopefully reduce infection rates as well as the toxicity associated, leading to higher 
numbers of long term survivors.  
Gene therapy is an option in the early stages of experimentation. Eleven patients with SCID 
were treated with a corrective lentiviral vector (140). Nine patients were cured but one 
developed a lymphoproliferative disorder (141). As such, effort in translating similar 
technology to the HLH field (142) should be done with utmost care and caution. Another 
interesting HLH treatment option currently in clinical trials is with an anti-IFN-γ antibody. 
This idea stemmed from reports showing blockade of IFNγ could increase the survival of 
perforin and Rab27a deficient mice (143,144). However, other models have shown that high 
IFN-γ does not necessarily lead to a HLH phenotype (18). Moreover, a recent report 
described two patients with IFN-γ receptor 2 deficiency but yet fulfilled HLH criteria (S.X). 
As such, further study is required to understand these observations. 
As the literature on HLH improves, primary HLH patients have been found with functional 
deficiencies in other cell types or organs not usually associated with host defense but could 
still contribute indirectly to the HLH pathology. For example, in some primary HLH patients, 
the gastrointestinal tract, erythrocytes, and platelets (145-147) have been shown to be 
affected. HSCT replaces not just CLs descended from the common lymphoid progenitor, but 
also macrophages, neutrophils, platelets, and red blood cells from the common myeloid 
progenitor. As such, other HSC derived cells affected by primary HLH (145,146,148,149) 
will be corrected, possibly leading to better overall standard of living post-transplant. Studies 
on the non-immunological functions of primary HLH genes are lacking, but it can be 
postulated that other cell types could utilize similar molecules for intracellular vesicle 
transport and exocytosis. Examples would include neurotransmission, excretion of digestive 
enzymes, and hormones from various organs/glands. Alternatively, hematopoietic cells could 
play important roles in various organ systems of the body that is yet unappreciated. Still, CL 
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most likely play a big role in HLH pathology and we next describe their function in relation 
to the work herein. 
 
1.6 The cytotoxic lymphocyte exocytosis pathway 
Natural killer cells and cytotoxic T lymphocytes can kill target cells through the secretion of 
lytic granules or via the FAS ligand pathway (150). In the case of granule secretion, which is 
the focus here, the effector cell first recognizes stress markers on the target cell through 
various receptors. Engagement of an activating receptor (Figure 1A) rapidly leads to ‘inside-
out’ signaling, altering lymphocyte function-associated antigen 1 (LFA-1) from a closed to an 
open conformation (151) (Figure 1B). Extended LFA-1 mediates adherence to the target cell 
and initiates the formation of an immune synapse (152), or to a vascular wall for 
extravasation and onwards to various targeted tissues (153). This event has been recently 
found to be potassium dependent (154). Engagement of the open conformation integrin then 
leads to ‘outside-in’ signaling that further activates the lymphocyte leading to polarization 
(155). 
Besides the LFA-1 activation, a phosphorylation signal cascade from the activated receptor 
would cumulate at the endoplasmic reticulum (ER) where Ca2+ is released from the ER into 
the cytoplasm. Lowering of the ER calcium concentration is sensed by stromal interaction 
molecule 1 (STIM1) and results in its aggregation. Aggregated STIM1 gathers ORAI1 
monomers on the cell surface, which bind into tetramers to form functional ion channels. 
Calcium fluxes into the cell in a process termed store-operated calcium entry (SOCE) (Figure 
1C). The Ca2+ influx activates calcinurin, a phosphatase which dephosphorylates NFAT, 
allowing this transcription factor to migrate into the nucleus where it mediates transcription 
of FasL, IFN-γ, TNF-α, IL-2, and chemokines (156,157). Besides lymphocyte signaling, 
ORAI1 is crucial for the proper function of airway epithelial cells (158), microglia (159), 
pancreatic acinar cell (160), and possibly many other cell types. ORAI1 deficiency has been 
identified in humans and its function heavily studied in Drosophila and mice (157,161). 
Work on human T cell lines demonstrated a role for ORAI1-mediated Ca2+ influx for 
induction of cytokine and chemokine expression. However, little is known about how crucial 
calcium signaling is in granule exocytosis by CL in general or NK cell function in particular. 
We had a chance to study NK cell signaling and function in a rare ORAI1 deficient patient 
and presented the results in Paper V. 
Signaling through activating receptors also leads to Fyn and ADAP activation, which control 
diverse downstream cell functions including cytotoxicity, proliferation, and cytokine 
production (162). Lytic granules in T cells are upon activation gathered to the MTOC via 
microtubules mediated by the motor protein dynein (163) (Figure 1D). Then the granules are 
transported to the polarized region on both microtubules and actin (164) via a complex of 
kinesin-1/Rab27a/Slp3 (165) (Figure 1E). Along the way, perforin-containing granules 
colocalize with vesicles containing Munc13-4 (S.I). The Rab27a/Munc13-4 complex is 
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required for granule tethering at the plasma membrane (166) (Figure 1F). Other molecules 
including Stx11 and Munc18-2 can then interact with the lytic granule (167) and most likely 
regulate the SNARE complex formation. This large complex mediates the fusion of lytic 
granule membrane and the cell membrane (Figure 1G).  
 
 
Figure 1. The cytotoxic cell response to a target cell. A virus infected ‘target’ cell triggers a 
‘effector’ cytotoxic lymphocyte via an activating receptor leading to multiple responses (A). LFA-1 
molecules through an inside-out activation would extend (B) to link to the target, forming the immune 
synapse. Calcium flux mediated CRAC and SOCE pathways (C) lead to production of cytokines and 
other stimulating factors. Lytic granules would be pulled towards the MTOC (D) and directed to the 
polarizing cell end (E) during which it associates with other factors including Rab27a and Munc13-4 , 
which are required for tethering (F). The actions of the SNARE complex including Stx11 and 
Munc18-2 (G) lead to docking and fusion of membranes. CD107a can then be found on the effector 
cell surface while perforin and granzymes are released into the immune synapse (H) where perforin 
acquires an active form and binds to the target cell membrane (I) and forms the MACPF. Granzymes 
enter the target cell through the perforin pores (J) and initiates target cell apoptosis. Illustration by Jin 
Ming Tee. 
Once the two sets of membranes fuse, the lytic granule content is released into the immune 
synapse and CD107a molecules attached to the inner membrane of lysosomes diffuse on the 
effector cell surface and can be detected by antibody staining (Figure 1H). This event is 
termed degranulation and represents a measure of CL activity (168,169). The whole multistep 
degranulation pathway is tightly regulated and removing one component collapses the whole 
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cascade. Target cell killing is thus abrogated, leading to disease progression. 
The immune synapse stably links the effector and target cell, allowing for precise 
unidirectional delivery of cytotoxic mediators directly aimed at specific target cells (170), 
minimizing bystander effect. This channel is most likely leaky but rapid dilution of perforin 
and granzymes outside the immune synapse renders them ineffective as these need to be 
colocalized and at a high concentration to be functional (171). 
The heavily glycosylated Lysosome Associated Membrane Protein (LAMP) family consists 
of CD107a (LAMP1), CD107b (LAMP2), and CD63 (LAMP3). The first two members 
together make up 50% of lysosomal membrane proteins (172). Upon exocytosis, the LAMPs 
diffuse onto the cell membrane in the vicinity of the immune synapse. Because they are found 
in such abundance, it has been suggested to be important in preventing perforin and 
granzymes from attaching and killing the parent cell (173). In addition, low lysosomal pH 
alters perforin structure rendering it inactive (174). CD107a has also been specifically found 
to be important for the maintenance of lysosomal compartment structure (175). In mice, 
knocking out CD107a did not result in significant pathology (176), possibly due to the 
redundancy offered by CD107b, which was upregulated. Knocking down both CD107a and b 
resulted in non-viable mice. CD107a could also play a role in the transport of lytic granules 
and the stability of perforin (177). In S.VI, where human cells were used, target cells forced 
to express surface CD107a were shielded from granule-mediated killing due to the inability 
of perforin to bind to the cell surface. Additionally, siRNA knock-down of CD107a led to 
poor NK cell cytotoxicity and increased effector cell apoptosis demonstrating that LAMP 
proteins do indeed confer protection against proteolytic damage. Multiple cancer lines (178) 
express surface CD107a and CD107b, and highly metastatic cells were found to be correlated 
with higher levels of surface CD107a and CD107b (179), suggesting again the protective 
nature of LAMPs. 
After traversing the immune synapse, perforin monomers change in conformation due to the 
more physiological extracellular pH and similar to the C9 complement component (180), 
oligomerize to form the membrane attack complex perforin (MACPF) on the outer surface of 
the target cell, similar to complement (181) (Figure 1I). Perforin would bind multiple calcium 
ions leading to a structural change that facilitates lipid binding (182). Once the pore forms, 
granzymes freely diffuse into the target cell and are able to directly induce apoptosis by 
activating caspases (183) (Figure 1J). 
The whole cytotoxic process happens relatively quickly with NK cells possibly being slightly 
faster compared to CTL (170). TCR recognition requires approximately two minutes (184) 
while cells targeted by NK cells show propidium iodide uptake in under two minutes (170). 
The whole process from initial target identification to target cell detachment has been 
estimated to last between six to eight minutes (61,185). It has been noted however that not all 
CL degranulate and are in fact very heterogeneous in terms of function. A minority of NK 
cells performs the majority of cytotoxic function while half of the NK cells observed did not 
kill any targets (186). Another study found CTLs have very varied killing rates and have long 
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moments of inactivity followed by ‘burst killing’ where multiple targets are killed in quick 
succession (187). As such, there is a need to study why certain cytotoxic cells function better 
than others and what leads to the vast heterogeneity. Cytotoxic cells with knocked-out 
perforin are incapable of mounting a killing response. When challenged, these CL have been 
found adhered up to 40 minutes to a target and repeatedly fluxed calcium. During this period, 
excessive amounts of cytokines was produced but no targets were killed (61). This possibly 
leads to the cytokine storm characteristic of HLH. 
Besides the established chromium release assay and the CD107a degranulation assay, many 
other measures of lymphocyte cytotoxicity have been developed. Amongst these, a granzyme 
B Enzyme-Linked ImmunoSpot (ELISPOT) assay detects the level of granzyme B secreted 
from effector cells after the addition of CL (188) while the GranToxiLux kit measures 
granzyme B directly in target cells. Another family of flow cytometric methods mimics the 
chromium release assay requiring a pre-labeling of target cells with a lipophilic dye before 
the addition of effector cell. Later, staining for dead cells allows separation of live and dead 
targets from effectors (189-191). The addition of other markers would allow for the 
discrimination of degranulating CL, early, and late apoptotic cells. All these methods have 
been tested to be ‘equivalent’ to the standard chromium assay, but there is currently no broad 
acceptance of any one technique which makes data comparison difficult. Moreover, most 
methods have not been tested in a diagnostic setting with primary cytotoxicity deficient 
patients.  
NK and T cells play different roles in the pathology of HLH as elucidated by mouse models. 
Knock-outs with a deficiency in one of the genes important for exocytosis leading to both 
defective NK and T cells are susceptible to severe HLH-like disease when challenged with 
LCMV (144,192), while mice lacking either cytotoxic NK or T cell did not show severe HLH 
symptoms when challenged (18). T cells specifically, have been found to be important in the 
controlling of antigen presenting cells and a major source of IFNγ secretion in HLH 
(144,193). NK cells on the other hand are important for the removal of inflammatory 
macrophages and hyperactivated T cells (18). Interestingly in mice with normal NK cells and 
perforin negative T cells, IFN-γ levels were elevated but HLH did not develop. This shows 
that both NK cells and T cells play different and non-redundant roles in the pathogenesis of 
HLH. 
In summary, the lack of NK cell and CTL cell cytotoxicity would lead to a susceptibility to 
malignancy, infections, and inadequate modulation of immune response. Hence, precise 
regulation of these killer cells, their various pathways, and activity is crucial for the well 
being of an organism. Herein we present work done on optimizing and creating new assays 
for the rapid, simple, and sensitive diagnosis of primary diseases associated with a defect in 
NK cell and cytotoxic T cell function. Starting off with an up-to-date step-by-step protocol 
for testing NK cell degranulation and perforin content (Paper I), we then present a multicenter 
European investigation into the sensitivity and specificity of the K562-NK cell degranulation 
assay in diagnosing primary HLH (Paper II). This diagnostic assay has been instrumental in 
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the discovery of novel noncoding mutations (Paper III, IV) and biological characterization of 
rare PID cases (Paper V). Finally, in an effort to study CTL cell function, a new 
degranulation assay was designed and the requirements for NK cell degranulation compared 
to CTL, in the context of primary HLH. This was performed with resting state cells without 
any prior activation (Paper VI). The accuracy of this T cell degranulation assay was then 
compared against established NK cell degranulation assays for the diagnosis of primary HLH 
leading to defective degranulation (Paper VII). 
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2 AIMS 
The work presented here aims at improving the current and developing new functional assays 
used for the diagnosis of hemophagocytic lymphohistiocytosis (HLH). This would lead to 
better patient management and improved prognosis. Studying how specific PID genes affect 
overall health is also important in broadening our general understanding of human biology. 
More specifically, our study objectives were: 
Paper I: 
• To provide an up-to-date standard operating procedure for performing NK cell 
phenotypic assessment and NK cell degranulation assay. 
Paper II: 
• To standardize NK degranulation assay protocols across the major HLH referral centers 
in Europe.  
• In a multi-center approach, to evaluate the K562-induced NK degranulation assay as a 
diagnostic assay for PIDs affecting NK degranulation. 
Paper III: 
• To evaluate all infant HLH cases in Sweden with defective NK cell degranulation. 
• To identify genetic defects in infant HLH cases that have yet to receive a molecular 
diagnosis. 
Paper IV: 
• To explain a rare case of HLH in a non-consanguineous family of Chinese descent.  
• To illustrate the effects of prolonged sample transport times on various cytotoxic 
lymphocyte functional assays. 
Paper V: 
• To understand the role of store-operated calcium entry in NK cell responses. 
• To determine the activation stage where ORAI1 function is crucial in NK cells.   
Paper VI: 
• To define a T cell subset containing cytolytic proteins that could exert cytotoxic effects. 
• To develop a robust CTL degranulation assay using resting, unstimulated lymphocytes 
and compare it to NK cell degranulation levels. 
• To study resting state and IL-2 activated CTL degranulation in patients with known NK 
cell degranulation defects. 
Paper VII: 
• To document the variability in responses to target cell stimulation found in various NK 
cell and CD8+ T cell subtypes. 
• To compare NK and CTL degranulation levels in various PID patients that present 
clinical HLH or hyperinflammation. 
• To assess the sensitivity and specificity of various degranulation assays for the diagnosis 
of primary defects affecting cytotoxic lymphocyte degranulation. 
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3 PATIENTS AND METHODS 
An overview of the patient groups studied and the methods employed in this thesis is outlined 
here. For specific details, please refer to the methods section of the various manuscripts.  
  
3.1 Patient recruitment 
Patients from Sweden and around the world were recruited for the studies done here. Through 
word of mouth and various channels, we have built up a network of clinician collaborators 
who send blood samples of their patients with suspected HLH or other abnormal 
presentations to us for diagnosis. The blood shipment included a signed consent as well as a 
short clinical report briefly outlining the patient’s current condition. Patients having 
confirmed functional and molecular diagnosis have been used for the papers presented here. 
The Regional Ethical Review Board in Stockholm has approved all studies. Healthy donors 
were obtained from the local blood bank. 
Specifically, in Paper I, II, VI, and VII, we have included patients bearing confirmed 
mutations leading to defective CL killing. For Paper III, we compiled all Swedish infants 
born between December 2005 and January 2011 referred to our laboratory for suspected 
HLH. Those with a family history of HLH and/or a defect in NK cell degranulation were 
included in the manuscript.  Also used were healthy local infant controls, confirmed PRF1 
patients, and European patients with mutations in UNC13D. Paper IV studied a specific 
family from Singapore diagnosed with a novel UNC13D mutation.  Paper V analyzed a 
patient previously reported bearing an ORAI1 mutation (194) as well as a patient with STIM1 
mutation. Paper VII included patients bearing mutations in PID genes leading to normal CL 
degranulation, patients being treated for MAS/SoJIA, and patients with at least 5 of 8 HLH 
criteria fulfilled but with no mutations in any HLH-associated genes. 
 
3.2 PBMC preparation 
In all papers, peripheral blood from patients, family members, and unrelated controls were 
collected in heparin tubes and delivered at room temperature within 48-hours to the 
laboratory. Whole blood was diluted 1:1 in phosphate buffered saline (PBS). The diluted 
blood was carefully layered on top of Ficoll in a 50 ml tube and spun at 800 g for 20 minutes 
with brakes off. The PBMC at the Ficoll interphase was then extracted, washed twice in PBS, 
and live cells counted, either with trypan blue on a haemocytometer, or using an automated 
cell counter (Muse, Millipore). Cells in complete media (RPMI supplemented with 10% heat-
inactivated fetal bovine serum and 2 mM L-glutamine) were then rested overnight or 
stimulated with 500U/ml IL-2 (Proleukin, Novartis) for 36-48 hours before assays were run. 
All unused PBMC were frozen down in fetal calf serum (FCS) with 10% DMSO and stored 
in liquid nitrogen for future work. Buffy coats were processed in a similar manner.  
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3.3 Cell isolation 
In Paper III, V, and VI where specific subsets of PBMC were evaluated, magnetic bead based 
isolation was used (Miltenyi Biotec). Paper III used positive selection magnetic beads for the 
isolation of CD4+, CD8+, CD14+, and CD56+ populations from PBMC. In Paper V and VI 
cells were purified using negative isolation kits. NK cells were isolated with a standard kit 
while CD8+ T cell subsets were purified using the standard CD8+ negative isolation kit 
supplemented with anti-CD45RO and anti-CD57 magnetic beads for naïve CD8+ T cells, 
with anti-CD45RA and anti-CD57 for memory CD8+ T cells, and with anti-CD28 beads for 
effector CD8+ T cells. Isolated fractions were tested for purity via flow cytometery before 
performing further work.  
 
3.4 Evaluation of NK cell cytotoxicity 
In Paper III, V, and VI, we evaluated NK cytotoxicity via the established 51Cr release assay. 
This sensitive and highly reproducible method (195) is still widely used for the determination 
of NK and T cell cytotoxicity although faced with problems involving radioactivity, waste 
disposal, a high cell number requirement, and the inability to be multiplexed. In this assay, 
cells (PBMC or purified subpopulations of NK or T cells) were incubated in medium or 
mixed with target cells (K562 cells, P815 cells, P815 cells added anti-CD3 mAb, L1210 cells 
alone, or L1210 cells added anti-CD16 mAb) pre-labeled with 51Cr (Na2CrO4, sodium 
chromate in normal saline, Perkin Elmer) at specific effector to target ratios. Effector cells 
were first serially diluted to a range between 100 and 0.3, before the addition of 51Cr-labeled 
target cells. To quantify spontaneous chromium release, pre-labeled target cells were 
incubated in media without any effector cells, while for maximum chromium release, pre-
labeled target cells were incubated with 2M hydrochloric acid. Assays were run in duplicates 
or triplicates for four hours in a humidified 37°C incubator. The cells were then spun down 
and supernatant collected for gamma irradiation quantification with a gamma counter 
(Packard, Cobra or Wizard2, Perkin Elmer).  
The specific percent lysis was calculated: 
% 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑙𝑦𝑠𝑖𝑠 =  𝑚𝑒𝑎𝑛 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑐𝑝𝑚 −𝑚𝑒𝑎𝑛 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑐𝑝𝑚𝑚𝑒𝑎𝑛 𝑚𝑎𝑥𝑖𝑚𝑖𝑢𝑚 𝑐𝑝𝑚 −𝑚𝑒𝑎𝑛 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑐𝑝𝑚  × 100 
cpm: counts per minute.  
The effector to target cell ratio at 25% specific lysis was estimated from the percent specific 
lysis curve, and converted to lytic units (LU) by the function below as described by Bryant et 
al. (196). A value of less than 10 LU25 was considered pathologic. 
Number of lytic units per 10! effector cells =  10!𝑛𝑜. 𝑜𝑓 𝑡𝑎𝑟𝑔𝑒𝑡 𝑐𝑒𝑙𝑙𝑠 × 𝐸:𝑇 𝑟𝑎𝑡𝑖𝑜 𝑎𝑡 25% 𝑙𝑦𝑠𝑖𝑠 
For detailed protocol, please refer to references 197 and 198. 
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3.5 Evaluation of cytotoxic lymphocyte degranulation 
In all papers, the evaluation of NK and T cell degranulation was performed via the detection 
of CD107a on CL cell surface after stimulation with various target cells (169,199). A 
complete and detailed protocol can be found in Paper I. Briefly, resting or cytokine 
stimulated PBMC were mixed 1:1 with target cells or media alone as control for up to 6 
hours. The target cells were K562, P815 with anti-CD16 antibody (clone 3G8), P815 with 
anti-CD3 (S4.1), or L1210 with anti-CD16 antibody in the presence of Brefeldin A. In Paper 
V, the SOCE blocker DPB162-AE was also added in certain experiments. The cells were 
then surface stained with a live/dead discriminating dye and fluorescence conjugated 
antibodies against CD107a (H4A3), CD3, CD4, CD8, CD56, and CD57. In certain 
experiments, LFA-1 open conformation (mAb24) was also evaluated. Cells were then fixed 
with formaldehyde (Cytofix, BD Bioscience), and stained for intracellular MIP-1β, CD69, 
TNF-α, and IFN-γ, in the presence of saponin (Cytoperm, BD Bioscience). Finally cells were 
acquired on a BD Calibur, Dako Cyan ADP, or BD Fortessa cell analyzer and analyzed on 
FlowJo (v7 or v9, TreeStar). The percentage NK/CTL degranulation or cytokine production 
was calculated by comparing effector cells stimulated with various conditions against effector 
cells in media alone, and termed ΔCD107a%. 
 
3.6 Evaluation of cell granule contents 
The detection of perforin levels in NK cells was performed with flow cytometry following 
the step-by-step procedure in Paper I. Resting PBMC were stained with a live/dead 
discriminating dye, and fluorescence conjugated antibodies against CD3 and CD56. Cells 
were then fixed with formaldehyde (Cytofix, BD Bioscience), and then stained for 
intracellular perforin (δG9), or isotype-matched control. Cells were acquired on a BD Calibur 
or BD Fortessa cell analyzer (BD Bioscience) and analyzed on FlowJo (v7 or v9, TreeStar). 
The median fluorescence intensity of perforin was then compared to isotype control. 
Advanced phenotyping of NK and T cells in Paper VI was performed as above but with 
additional surface and cytoplasmic markers including CD3, CD4, CD8, CD27, CD28, 
CD45RA, CD45RO, CD62L, perforin, and granzyme B. Data was evaluated using Spice 
v5.2b 21265010 and the probability state modeling performed by Gemstone (v1.0.63, Verity 
Software). Details on the models are found in the supplementary data of Paper VI. 
 
3.7 Calcium flux 
The detection of intracellular calcium levels in Paper V was done with indo-1-AM. Isolated 
NK cells were first preincubated with thapsigargin, a calcium inhibitor, or anti-CD16 
antibody before being spiked with CaCl2. Cells were acquired on an LSRII (BD Bioscience). 
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3.8 DNA sequencing 
Mutation detection for most of the patients analyzed was performed via PCR followed by 
Sanger sequencing. Genomic DNA was isolated from peripheral blood, fibroblasts, or PBMC 
according to standard procedures. Forward and reverse primers were designed to amplify 
exons and exon-intron boundaries of the known FHL genes by PCR. In Paper III and IV, 
primers targeting evolutionary conserved intronic regions of UNC13D were in addition 
designed. PCR products were then directly sequenced (BigDye v3.1, Applied Biosystems) 
and reactions analyzed by capillary electrophoresis (ABI3730, Applied 
Biosystems).  Variants found were assessed in silico for pathogenicity using the program 
Alamut (Interactive Biosoftware). For a small number of patients in Paper VII, whole exome 
sequencing was performed. Sequences were processed through a bioinformatics pipeline 
including quality control, mapping, coverage analysis, variant calling, variant annotation, and 
filtering. Reads were mapped to genome build hg19. Potential candidate variants were 
inspected visually and thereafter confirmed with Sanger sequencing. 
 
3.9 RNA isolation and cDNA amplification 
In Paper III, total RNA was extracted from PBMC (RNeasy, Qiagen) and first strand cDNA 
synthesized with oligo(dT)20 primed reverse transcription (SuperScript III, Invitrogen). Nine 
primer pairs were designed to amplify overlapping cDNA fragments of the UNC13D cDNA. 
The amplified products were run on an agarose gel, extracted (QIAquick, Qiagen) and cloned 
(TOPO-TA, Invitrogen). The resulting plasmid DNA was then extracted and sequenced. 
The 3’ RACE-PCR (Rapid Amplification of cDNA Ends) used primers marked with an 
M13R-tag for the first strand cDNA synthesis. Then the 3’-end amplification was carried out 
with a gene specific forward primer and an M13R reverse primer. The amplified products 
were then similarly ran on an agarose gel, extracted, cloned and sequenced as described 
above. 
 
3.10 Allele specific  RT-PCR 
For Paper III, trizol extracted RNA from various isolated subpopulations of lymphocytes was 
used for cDNA synthesis as described above. Quantitative real-time PCR was then run to 
quantify allele specific transcription levels. Two different reverse primers that could 
differentiate a single nucleotide polymorphism in exon 11 (c.888G > C) were used. cDNA 
was mixed with SYBR Green PCR mix (Applied Biosystems) together with forward and 
reverse primers. Reactions were ran on a real-time PCR (ABI7900 HT, Applied Biosystems) 
in triplicates. 
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3.11 Western blot 
PBMC from various patients in Paper III and IV were blotted for Munc13-4. PBMC were 
lysed with buffer containing Triton X-100 and then spun down to collect the supernatant. 
Protein content was first determined using Bradford assay (Bio-Rad) and equal protein 
amounts then loaded onto an SDS-PAGE gel. The gel was transferred to a nitrocellulose 
membrane and blotted for Munc13-4 (Protein Technologies Group) and ERK1 (Santa Cruz 
Biotechnology).  
 
3.12 Granule polarization assay 
In Paper V, isolated NK cells were incubated with K562 cells for 20 minutes on a microscope 
slide and then fixed with paraformaldehyde. Phalloidin, perforin, and α-tubulin were stained 
for and conjugates imaged with a confocal microscope. The degree of actin, perforin, and 
MTOC polarization was then scored. 
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4 RESULTS AND DISCUSSIONS 
The following chapter gives an overview of the patient samples analyzed over the years in 
our laboratory. Besides collating the data from papers included in the appendix of this thesis, 
select observations from our other published and yet unpublished works have been included 
here to so as to present a fuller picture of the diagnostic efforts.  
 
4.1 Patient census 
Over the past seven years, we have built up a strong network of clinician collaborators from 
around the world. This has led to a large number of HLH diagnostic requests. The 
geographical origin of patients received between the period of January 2013 and July 2015 is 
shown in Figure 2. During this period, 421 unique patients were received in 31 months or an 
average of 13.6 patients a month. This number does not include repeat samples or those from 
family and healthy controls shipped at the same time.  
Local Swedish patients represent the highest proportion. Most of these patients do not fulfill 5 
of 8 HLH criteria but with high awareness amongst local clinicians, samples have been sent 
in due to reoccurring infections, hyperinflammation, and abnormal clinical symptoms. This is 
important in light of reports of PID patients with atypical presentation (S.IV, S.IX, S.X, 
S.XIII). Substantial patient numbers have also been sent from our Scandinavian neighbors. 
Consanguinity is uncommon in this region (200-202) but small initial founder populations 
combined with genetic isolation or large immigrant populations with limited integration to 
indigenous populations have led to enrichment of certain monogenic diseases (92,203,204). 
Turkey and Poland also contributed a significant number of patients. These are two populous 
countries (78 and 38 million inhabitants respectively, compared to 25 million in Denmark, 
Finland, Norway, and Sweden combined) and have naturally higher number of cases. 
Additionally, up to a third of marriages in Turkey are consanguineous (205). With ease in 
travel between Schengen states and large migration from places of unrest, European countries 
have become more heterogeneous. Such populations tend to produce offspring within the 
same race group that could lead to higher rates of consanguinity, and in the case of Norway, 
40% of children born to Pakistani migrants have related parents (200). 
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4.2 Assay advancement for rapid assessment of genetic degranulation defects 
CD107a is a protein usually found associated with lytic granules and late endosomes. Upon 
degranulation, where the membrane of lytic granules fuse with the plasma membrane, 
CD107a can then be found on the outer cell surface and detected easily.  Should there be a 
damaging mutation in one of the genes implicated in lytic granule trafficking or membrane 
fusion, CD107a surface expression would be absent or greatly reduced after target cell 
stimulation. This is the biological basis behind the functional assay to diagnose for genetic 
degranulation defects.  
When diagnostic assays were first run in our laboratory, CD107a levels on NK cell surface 
was studied using a 4-colour cytometer (Paper II and III). The European consortium in Paper 
II met to standardize protocols between four collaborating laboratories and agreed upon a 
basic degranulation assay consisting of two conditions, first a negative control of PBMC with 
no stimulation, and the second having PBMC with K562 cells as stimulus. Patients were 
analyzed at the various laboratories for 2½ years before the data was collated. The 4 
laboratories contributed in total 120 confirmed PID patients of which 90 carried a genetic 
degranulation defect. Comparing these against a group of patients with secondary HLH, XLP, 
or PRF1, Receiver operating characteristic (ROC) curves returned 5.4% CD107a+ NK cells 
as the optimal threshold giving 96% sensitivity and 88% specificity for the discrimination of 
genetic degranulation defects. Degranulation results from patients with secondary HLH, 
XLP, and PRF1 showed no difference when stratified into groups not on medication, 
receiving immunosuppression, or treated with the HLH-2004 protocol. This showed that the 
degranulation readout was robust and not affected by treatment.  
Acquisition of a 4-laser BD Fortessa with 20 channels allowed for an improved assay with 
the additional quantification of cytokine production (MIP-1β, TNF-α and IFN-γ) as well as 
cell activation status (LFA-1 and CD69) in both NK and T cell subsets (Paper I, V, VI, and 
VII). Thus, multiparametric flow cytometry opened the door to multiple readouts, allowing us 
to obtain more data from the same number of cells. These cytokine markers encompass a 
wide activation time-range, with the inside-out LFA1 being a very early activation marker 
found on NK and CTL surface after target detection (S.III) followed by CD69 and MIP-1β 
upregulation. Lastly, between 2 to 3 hours, TNF-α and IFN-γ will be detectable in CL (Paper 
I, V, and VI).  
Having an assay with multiple readouts representing various periods of cell activation and 
response is important for the thorough characterization of novel primary deficiencies. ORAI1 
and STIM1 have been identified as the molecular constituents of the calcium release-
activated calcium (CRAC) channel in T cells (157). This channel regulates Ca2+ influx into 
the cell, which is essential for activation and cytokine expression. As the role of ORAI1 in 
cytotoxic lymphocyte degranulation and killing in general, and NK cell development and 
function more specifically had not been studied, we ran an expanded degranulation panel on 
PBMC from an ORAI1 deficient patient and found a defect in both NK cell cytokine 
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production and degranulation when challenged with K562 (Paper V). Patients with genetic 
defective degranulation normally do not show reduced cytokine production (Paper VII). The 
inside-out LFA-1 activation (S.III) was however intact in the ORAI1 deficient NK cells as 
this very early signaling is calcium independent. Besides highlighting the importance of 
calcium in NK cell function, our results thus suggest ORAI1, and not other Ca2+ channels, is 
the predominant CRAC and crucial for both cytotoxicity and cytokine production. 
While compiling data for Paper II, the lack of a robust CTL degranulation assay became 
apparent. A T cell degranulation protocol relying on PBMC to be stimulated for 2-3 days 
with IL-2 and PHA followed by a Ficoll to remove dead cells and a further 2-3 days of low 
level IL-2 stimulation before being tested for degranulation using CD3/28 coated beads had 
obvious shortcomings as a diagnostic assay. Besides being tedious and very labor intensive, it 
was neither rapid nor sensitive for the detection of degranulation deficiencies. We have 
shown that stimulation with IL-2 leads to functional recovery in certain UNC13D (Paper III), 
STX11 (S.VII,66), and STXBP2 (S.II, S.V). Thus, normal levels of degranulation found in 
activated T cells could simply be a recovered degranulation deficit, and this assay would fail 
to diagnose those patients. This led to a desire to create a T cell degranulation assay that is 
easy to perform and utilized fresh unstimulated cells.  
In Paper VI, CD57 was found to be a cell surface marker that positively correlated with 
internal levels of perforin and granzyme B in T cells, corresponding to a highly differentiated 
CD27–CD28–CD45RA+CD45RO– effector T cell population. More importantly, freshly 
isolated CD3+CD8+CD57+ cells responded to anti-CD3 antibody stimulation by 
degranulating as well as producing high levels of cytokines. This ‘resting state’ cytotoxic T 
cell response (degranulation and cytokine production) was more rapid and vigorous 
compared to CD56dim NK cells stimulated with anti-CD16 antibody, with more 
multifunctional CD8+CD57+ cells compared to NK cells. Isolated naïve, effector, and 
memory subsets of CD8+ T cells were tested for specific cytotoxicity and only the effector 
CD57+ subset displayed substantial anti-CD3 antibody mediated killing of target cells. When 
tested on patients with known molecular defects in UNC13D, STX11, and STXBP2, both NK 
cell and CD8+CD57+ T cell degranulation were abolished in resting unstimulated PBMC 
(Paper IV, VI, VII). Probed further, patients whose NK cell degranulation recovered with IL-
2 stimulation likewise regained function to a similar extent in the CD8+CD57+ T cell 
compartment (Paper VI). We concluded that there are similar requirements for Munc13-4, 
Syntaxin-11, and Munc18-2 for both NK cell and CD8+CD57+ T cell function. 
It was then reasoned that this new cytotoxic T cell degranulation assay could be useful for the 
diagnosis of deficiencies leading to degranulation defects. Hence, all molecularly confirmed 
PID patients analyzed between November 2011 (when the CTL degranulation assay was 
started) and December 2014 were collected and presented in Paper VII. The patients were 
divided to two groups; those carrying genetic defects that led to a CL degranulation 
deficiency, and patients with molecular defects not affecting CL degranulation. As further 
controls, three other groups were selected. First a cohort of 200 healthy donors from the local 
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blood bank, second a cohort of patients being treated for MAS/SoJIA as well as patients 
fulfilling HLH criteria but with no mutations found in any PID gene, and thirdly all healthy 
unrelated controls that were shipped together with patient samples.  
Three different degranulation assays were performed on all samples, NK cell stimulation with 
the K562 cell line (natural cytotoxicity), NK cell stimulation with the P815 cell line together 
with anti-CD16 antibody (ADCC), and CD8+CD57+ T cell stimulation with the P815 together 
with anti-CD3 antibody (TCR stimulation). Surface CD107a expression as well as internal 
cytokine production was measured after 3 hours. Sensitivity and specificity of each 
degranulation assay were obtained by comparing patients with genetic degranulation defects 
against patients with other PIDs not affecting degranulation, as similarly done in Paper II. 
The ROC results are summarized in Table 3. 
 
Table 3. ROC analysis on the various assays assessed. Data shows results from cohorts analyzed in 
Paper II and VII.  
Study 
Cell type 
evaluated 
Stimulation 
Cutoff 
(ΔCD107a%) 
Sensitivity 
(%) 
Specificity 
(%) 
Paper II NK K562  5.4 96 88 
Paper VII NK K562 7.9 86 97 
Paper VII NK 
P815 with 
anti-CD16 
12.5 97 92 
Paper VII CTL 
P815 with 
anti-CD3 
23.5 97 95 
 
All assays ran gave good sensitivity and specificity. In Paper VII, the CTL degranulation 
stood out as the best overall while K562 lagged in sensitivity. Anti-CD3 antibody stimulation 
led to a stronger CTL degranulation response as seen with the higher cutoff compared to NK 
stimulation while anti-CD16 gave higher signal compared to K562 on NK cells. The higher 
signal to noise is appreciated when running assays on samples shipped from distant countries 
and have undergone transport stress. CL under stress did not degranulate well especially for 
the K562-induced degranulation (Paper IV, VII). This also led to poor chromium release 
assay killing values as it is also based on NK cell response to K562. Not only do more 
CD8+CD57+ T cells degranulate compared to NK cells when stimulated, they also 
degranulated more, displaying higher CD107a median fluorescence intensities (Figure 3). 
This would aid in the detection of hypothetical deficiencies that would lead to partial loss in 
CL degranulation.  
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A noticeable difference appears between the results from the K562 degranulation in Paper II 
and Paper VII. In Paper II, the assay was incubated for 2 hours compared to 3 hours in Paper 
VII to allow for cytokine detection. Secondly, the results in Paper II represents pooled data 
from 4 different laboratories with slightly different protocols, equipment, analysis method, 
and staff. Samples arriving at our lab were previously ran on the same day it arrives during 
the Paper II study period but are now rested overnight before running. Lastly, in Paper II, it 
was found that the K562 line from Stockholm gave lower levels of degranulation as 
compared to lines from other centers. As such, we have switched to using the K562 line that 
gave the highest level of degranulation.  
 
 
Figure 3. Defective degranulation in a STXBP2 patient. Degranulation plots from a healthy person 
and a patient with compound heterozygous mutations in STXBP2 (c.1463C>T, c.37+2T>C). More 
cytotoxic T lymphocytes degranulate, and to a higher median fluorescence intensity (MFI) as 
compared to NK cells when stimulated with K562 or P815 with anti-CD16 antibody. 
 
Many infants between 0 – 3 mo have low CD8+CD57+ T cell counts as consequence of 
immunological immaturity. A census of all patients received in 2014 returned 16 patients 
analyzed at an age of 0 - 3 mo. Of this, 2 have low NK numbers while 7 have low 
CD8+CD57+ T cell number. A low count is defined as lesser than 100 gated NK/CTL per 
stimulation, out of 200,000 PBMC at the start of the assay. Scanning through 152 unique 
patients in 2014, regardless of age, found 17 patients had both low NK and CTL numbers, 23 
had low CTL only, while 6 patients had poor NK numbers only. Thus, if only one of the three 
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different degranulation assays were run and insufficient cytotoxic cell numbers were 
acquired, a resampling would have to be arranged, leading to loss in time and waste of 
reagents besides additional patient stress. We hence suggest that at least two degranulation 
assays be run simultaneously to act as a safeguard against the failure of one of the assays due 
to poor cell numbers or human error, as well as for confirmation. The two assays suggested 
would be NK cell degranulation by anti-CD16 antibody stimulation and CD8+CD57+ T cell 
degranulation by anti-CD3 antibody stimulation. From Paper VII, should these two assays be 
run concurrently, a 94% sensitivity and 100% specificity is noted. 
Although the NK cell CD107a assay has been validated for diagnosis of genetic 
degranulation defects (Paper II), it has been known that large variability exists for the level of 
NK cell response to K562 cell stimulation (Paper VII). We have recently published data 
showing NK cells displaying functional heterogeneity in a subset of CMV positive healthy 
individuals (S.XI). Specifically, NK cells with epigenetically downregulated EAT-2 or FcεRγ 
showed normal cytokine production but reduced CD107a degranulation upon stimulation 
with K562 cells. This effect was less pronounced with anti-CD16 stimulation. In Paper VII 
where 200 random healthy blood bank donors were screened, two persons with the highest 
percentage of FcεRγ downregulation in NK cells had K562 induced degranulation below the 
7.9% diagnostic cutoff for genetic defective degranulation. Both individuals had normal anti-
CD16 NK and anti-CD3 CD8+CD57+ T cell response This implies that approximately 1% of 
the healthy adult population could be falsely diagnosed with a degranulation defect should a 
large-scale K562-only screening be attempted. Once again, caution should be taken when 
relying on one sole degranulation assay for diagnosis. 
Although the basis of the routine assays performed has not changed throughout these years, 
many small steps had been taken to improve the standard operating procedure. Compounded 
small changes can sometimes lead to huge differences. PBMC isolated from blood samples 
were previously immediately run on the same day but now left to rest overnight. This led to 
better degranulation and killing responses from healthy persons. Instead of using PBS for 
blood dilution and PBMC washes, we have started using whole RPMI media, giving up to 2 
fold higher viable cell counts. Cell counting has also transitioned from the conventional 
haemocytometer to automated flow-based counting. This is more accurate and reproducible, 
removes human error, and allows us to confidently enumerate exact live PBMC numbers as 
the machine ignores RBCs, debris, and dead cells. These issues are especially important in 
samples from very ill patients or poor transportation that sometimes showed RBC 
contamination in the ficoll layer. A complete blood count including specific lymphocyte 
subsets is done on every sample to precisely ascertain the percentage of NK and CD8+CD57+ 
cells. Samples with exceptionally low CL numbers would require the use of more PBMC for 
the assays in order for there to be enough cells for analysis, reducing assay failure rates.  
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4.3 Cytotoxic lymphocyte function in primary HLH 
Patients with biallelic defects in one of the FHL associated genes (PRF1, UNC13D, STX11, 
and STXBP2) or genes linked to partial albinism (LYST, AP3B2, and RAB27A) show 
defective NK cytotoxicity. These patients commonly present with fulfilled clinical HLH 
criteria. Here we highlight our contribution to characterize and understand some of these 
deficiencies. 
When initially identified, FHL was thought to be a severe disease that manifested only in the 
first years of life (65). Later, persons with defective CL function were found as late as the 
fourth to sixth decade of life (S.XIII,206). Data from patients analyzed for Paper VII showed 
approximately 2/3 of degranulation deficiency cases were ≤ 2 years old at time of sampling 
while 2/3 of other PID with no degranulation deficiency were ≥ 2 years old (Figure 4). 
Degranulation deficiency syndromes are thus more common in infants and adult cases of PID 
are less common but age cannot be used as an exclusion criteria. 
 
 
 
 
 
 
 
 
 
 
Figure 4. Age of patients and controls analyzed in 
Paper VII. Brackets indicate percentage of patients in each 
group with an age of ≤ 2 years old at time of analysis. p 
value calculated using nonparametric Mann-Whitney t-test. 
Green points represent patients with hypopigmentation 
(LYST, AP3B2, and RAB27A) while red points represent 
perforin deficient patients (PRF1). DEG: patients with a 
genetic degranulation defect, PID: immunodeficiencies not 
presenting with defective degranulation. 
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4.3.1 Perforin, PRF1 
The lack of perforin, a syndrome termed FHL2, leads to defective cytotoxicity but unaffected 
levels of CL degranulation. It is thus used in Paper II, III, VI, and VII as a control group 
presenting HLH and having defective cytotoxicity but with normal degranulation. Perforin 
can be directly stained for in NK and T cells and is accurate for the diagnosis of FHL2 (207). 
Staining with the dG9 antibody clone was sensitive for the detection of various perforin 
deficiencies, rare variants, and certain heterozygous carriers (Figure 5). The relative perforin 
expression in these patients’ NK cells correlated to cytotoxicity against K562, as 
demonstrated by the lytic units at 25% specific lysis (LU25). 
 
Figure 5: Perforin staining in NK cells from families with various PRF1 mutations. A) A 3 mo 
patient with homozygous c. 445G>A mutation leading to total loss of perforin but normal levels in the 
heterozygous parents B) A 6 yo patient with homozygous c.1349C>T, with parents being 
heterozygous carriers C) 38 yo Patient with homozygous A91V with a heterozygous sibling, D) A 
family with both 7 mo patient and father heterozygous for the rare variant c.706 C>T and displaying 
reduced perforin levels. Brackets display LU25 values for representative plots. 
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There is a large variation in the age at presentation as well as clinical spectrum of patients 
with perforin mutations. Typically, patients with nonsense mutations would present HLH 
earlier in life while it is possible for persons carrying biallelic missense PRF1 mutations to be 
completely healthy. Three sibling pairs were found in our records where each pair carried 
similar PRF1 mutations but with different clinical manifestations. One sibling in each pair 
was affected by HLH. For the other sibling, two of three developed Hodgkin’s lymphoma 
while the third remained healthy (S.XIII). Another unrelated 19 yo patient analyzed was 
found carrying homozygous c.394G>A and interestingly did not have HLH but presented 
with reoccurring fevers and headaches, leading to refractory seizures, blurring of vision in the 
right eye, and right-side hand weakness.  A brain MRI detected multiple lesions as well as 
abnormal leptomeningeal thickening in the interfolial spaces. These neurological symptoms 
were cured after a matched related allogeneic hematopoietic stem cell transplantation (S.IX). 
Comparing a cohort of perforin patients with biallelic nonsense mutations against perforin 
patients with biallelic missense mutations, the nonsense cases had a disease onset of < 1 yo 
while the missense cases had a later age of presentation (22 mo – 38 yo) (S.XIII). More 
importantly, NK cell function assessed by chromium release assay showed recovery after IL-
2 stimulation in the cohort with missense mutations. Examining CL after IL-2 stimulation 
found a noticeable recovery in perforin in a patient where cytotoxicity improved (Figure 6). 
Evaluation of NK degranulation by CD107a is not informative as PRF1 patients have normal 
degranulation. All together, this fits well with the hypothesis that missense mutations in 
PRF1 are in fact a protein-misfolding disease (208). It remains to be understood how IL-2 
stimulation corrects for misfolded perforin in CL in certain patients. 
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Figure 6: IL-2 mediated recovery of perforin expression leads to regained cytotoxicity. A) A 
patient bearing homozygous. c.673C>T with minimal perforin recovery in CLs after IL-2 stimulation 
shows no improvement of cytotoxicity as shown in brackets (LU25), while in B) a patient with 
c.148G>A, c.673C>T displays substantial perforin upregulation after IL-2 stimulation and likewise 
improved LU25 with a healthy control as reference. Filled graphs represent isotype control. 
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4.3.2 Munc13-4, UNC13D 
Biallelic mutations in UNC13D, STX11, STXBP2, LYST, RAB27A, and AP3B1 can be 
functionally diagnosed by a standard NK or CD8+CD57+ degranulation assay. A patient 
showing lowered NK or CTL degranulation or poor cytotoxicity would trigger targeted 
sequencing of these genes. To save resources and effort, only the exons and intron-exon 
boundaries were usually sequenced.  
Two Swedish infants (<2 yo) fulfilling HLH criteria with defective NK cell degranulation 
and cytotoxicity were sequenced for all known HLH genes but only monoallelic UNC13D 
mutations were found (Paper III). Western blot showed these patients did not express any 
detectable Munc13-4 protein and so we asked if the gene was transcribed normally. Specific 
overlapping segments of the UNC13D mRNA were amplified and in one of these two 
patients, the last two segments failed to amplify. To solve this, a 3’ RACE PCR was ran and 
the sequence mapped to reveal a 253kb inversion. To the best of our knowledge, this 
represents the first description of an autosomal recessive human disease caused by an 
inversion. The second monoallelic patient had normal mRNA transcription and so all highly 
conserved intronic regions of UNC13D were next mapped and sequenced. Surprisingly, an 
intronic point mutation c.118-308C>T was found in a highly conserved region of intron 1. 
Re-sequencing unsolved HLH cases revealed six infants carrying homozygous 253-kb 
UNC13D inversion. As such, it is now the most common mutation found in primary HLH 
cases in Swedish infants (13/26 alleles). Screening through 190 healthy adult Swedes found 1 
heterozygous person or approximately half a percent of the population. Microsatelite 
mapping revealed a common haplotype in patients of Scandinavian ancestry suggesting a 
founder effect from northern Scandinavia. Following this, a proof of principle Guthrie card 
based screening for the inversion mutation has been designed and tested (209). This is in line 
with the unusually high UNC13D inversion incidence in Sweden that was close to that of 
SCID (210). The screen was found to be very accurate and may be implemented in the 
Swedish neonatal screening program. 
Re-sequencing patients for the intronic mutation found hits from Denmark, Slovenia, and 
Croatia. Microsatelite analysis again found similar signatures suggesting a common heritage. 
A Korean national study then reported the c.118-308C>T intronic point mutation as the most 
common mutation found in Korean UNC13D patients and SNP analysis likewise suggested 
an independent Korean founder effect (211). The same group postulated earlier that 
conventional sequencing likely missed mutations in the second allele (212).  
Later, we found an 8 yo ethnic Chinese patient carrying a point mutation one base pair 
downstream at position c.118-307G>A (Paper IV). The patient rapidly digressed and died. 
An elder brother was found to carry the same mutations but is currently asymptomatic at 15 
yo. He was recommended for HSCT as the underlying molecular defect predisposed him to 
rapid-onset HLH as well as malignancy (S.V). However, the family declined. Following this, 
the Cincinnati Children’s hospital published genetic data on a large cohort of 1709 suspected 
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HLH cases and reports that the two intronic mutation and the inversion mutation together was 
found in 31.6% of all UNC13D patients (213). In addition, a patient with a novel point 
mutation in intron 28 was reported, suggesting that non-coding mutations are in fact more 
common than thought, at least in UNC13D. It also draws attention to the possibility of missed 
mutations in reported monoallelic or hypomorphic cases (44,95,214). 
The pathogenesis of c.118-307G>A and c.118-308C>T mutations was next studied (S.VIII). 
UNC13D gene transcript could be amplified indicating the mutations did not interfere with 
splicing while real-time PCR on sorted lymphocyte subtypes found transcription severely 
reduced specifically in CD4, CD8, and CD56 populations but not in CD14 cells. Next, a 
transcription factor binding prediction software found the mutated region to be a predicted 
consensus ELF1 binding site. ELF1 facilitated STAT4 binding and together recruited BRG1, 
leading to the acetylation of surrounding chromatin. The relaxed DNA allowed gene 
transcription to proceed. Both STAT4 and BRG1 were highly expressed in T and NK cells 
but not monocytes, supporting the real time PCR finding. In addition, a novel second 
transcription start site was found in intron 1 and transcription from this start site was 
abrogated by the point mutations. The function of alternative Munc13-4 isoforms are 
currently being investigated in the laboratory.  
One curious observation was the partial recovery of NK cell cytotoxicity in patients bearing 
the 253-kb inversion mutation (Paper III). This recovery was not seen in patients with the 
c.118-308C>T intronic point mutation or other UNC13D coding mutations. This small 
increase in degranulation led to a large increase in cytotoxicity, which remains unexplained. 
In conclusion, the establishment of sensitive assays for the detection of NK degranulation 
(Paper I, II) led us to discover novel non-coding mutations in the UNC13D gene (Paper III, 
IV). The high prevalence of these mutations in the Scandinavian population argues for 
compulsory neonatal screening in Sweden in the hope of early intervention. European, Asian, 
and North American diagnostic centers had similarly found substantial numbers of patients 
bearing these non-coding mutations in their cohort, improving their diagnostic capabilities. 
Biochemical studies have found STAT4 recruitment abrogated by the intronic point 
mutations leading to poor DNA uncoiling and transcription at the UNC13D locus in CL. The 
study of rare diseases utilizing powerful functional assays are thus not just diagnostic, they 
also shed light on basic cell function. 
 
4.3.3 Syntaxin 11, STX11 
Patients with defects in STX11 are labeled FHL4 and these mutations lead to a range of 
reduction in CL degranulation, depending on mutation severity (Paper VI,215). All STX11 
patients analyzed in our laboratory showed partial recovery of NK cell degranulation after IL-
2 stimulation (S.VII,66). As seen, there is a trend for better K562-induced NK degranulation 
recovery compared to other stimulations (Figure 7).  
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Figure 7. Degranulation of resting and IL-2 stimulated CL from STX11 patients. PBMC from six 
patients with STX11 biallelic mutations were stimulated with K562, P815 with anti-CD16, or P815 
with anti-CD3. Results show the CD107a percentage after subtracting basal level degranulation. 
Patient numbers arranged to indicate increasing age from 0 to 7 years old.  
 
The precise role of various FHL-associated proteins and their domains crucial for cytotoxic 
function is still largely unknown. Studying point mutations found in various domains is one 
way of deciphering protein function. STX11 patients with N-terminus missense mutations 
were found lacking Munc18-2 interaction. Without this stabilizing interaction, we suspected 
Stx11 would be degraded and hence not detected by Western blot (S.VII). Similar to 
deficiencies in UNC13D and STXBP2, it is still unclear how IL-2 stimulation led to 
functional recovery.  
 
4.3.4 Munc18-2, STXBP2 
The STXBP2 gene codes for Munc18-2 and is the latest member of the FHL syndrome group, 
called FHL5. A census of 11 STXBP2 patients found variable age of onset (2 mo to 17 yo) 
and clinical presentation (S.II). Besides immunological changes, various neurologic 
symptoms were noted in half the patient population and gastrointestinal symptoms including 
chronic diarrhea, vomiting, and abdominal pain in 6 of 11 cases. Interestingly, the 
gastrointestinal symptoms resolved after commencing HLH treatment with no reoccurrences 
in one patient 8 years post transplantation. These chronic symptoms predate HLH 
manifestation and clinicians should be aware that such could point to possible 
immunodeficiencies as described in S.IX. These proteins traditionally linked to cytotoxic 
function may play unknown roles in the brain and gastrointestinal system. However, the fact 
that HSCT led to the resolution of most symptoms in these patients suggested that the 
pathology was driven by hematopoietic cells with defective Munc18-2 function.  
The oldest patient enrolled in the above study developed a nearly fatal EBV triggered HLH 
but recovered with HLH-94 treatment. She was not transplanted due to her late onset and 
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relatively stable health after the initial attack (S.V). As seen in Figure 8, this patient showed 
very robust IL-2 mediated NK and T cell degranulation recovery with IL-2 stimulated values 
comparable to healthy donors. This is not the general trend seen in other STXBP2 patients 
(Figure 9). Almost four years later, a rapidly developing classical Hodgkin’s lymphoma was 
detected in the cervical lymph nodes. After treating the lymphoma, she was transplanted and 
today, 2 years post-transplant, she is doing well. It is postulated that robust recovery of 
function might confer partial protection leading to severe disease only later in life. Patients 
bearing milder mutations could escape severe HLH during infancy but have a higher chance 
of developing malignancies, neurological, gastrointestinal, and other diseases with age. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Repeated evaluation of an adolescent STXBP2 patient. Resting and IL-2 stimulated NK 
cell and T cell degranulation are plotted next to 30 healthy controls ran during the same period. 
Activated cells from the patient showed strong functional recovery. Bar graphs depict data from 
healthy controls while dots represent repeated patient samples taken over a 2-month period. 
 
Similar to STX11 patients, some STXBP2 patients recover function with IL-2 stimulation. The 
induced recovery of K562 degranulation seemed better than anti-CD16 or in T cells (Figure 
9). It is however difficult to correlate age of onset with IL-2 recovery or genotype.  
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Figure 9. Degranulation of resting and IL-2 stimulated CL from STXBP2 patients. PBMC from 
eight patients with STXBP2 biallelic mutations were stimulated with K562, P815 with anti-CD16, or 
P815 with anti-CD3. Results show the CD107a percentage after subtracting basal level degranulation. 
Patient numbers arranged to indicate increasing age. Patient 8 was evaluated at 17 yo while all others 
were at 6 mo or below. 
 
4.4 General discussion  
The data provided demonstrated that certain patients in all the various FHL subgroups 
showed recovery of function after IL-2 stimulation. It was however difficult to predict which 
would recover, and the degree of recovery. Correlating the mutation, age, clinical symptoms, 
or resting functional results did not clearly predict the level of functional recovery. The 
collection of more patient data would hopefully facilitate better prediction. 
Searching our database for siblings having similar mutations in genes involved in cytotoxic 
cell degranulation (not perforin), we found three families. The functional results for these 
pairs are shown in Table 4. In most cases, one sibling was found manifesting HLH while the 
other sibling was either asymptomatic or presented atypical symptoms. We expected the 
siblings to show roughly similar levels of NK and T cell degranulation but found variable 
activity especially in IL-2 stimulated cells. Additionally, the sibling that came down with 
HLH not necessarily had poorer function. Again, there was a disparity between clinical and 
functional data. The interplay of other genes, diet, and epigenetic factors most likely led to 
this finding. In a recent study, a team of researchers took 7 years to create 1400 RNAi worm 
knock-outs on two different strains (216). Significant differences in the phenotype severity 
was found in 20% of gene mutations between the two strains of worms. This was partly due 
to varying gene expression levels between the two strains. As humans have heterogeneous 
genetic backgrounds with large variations in gene expression, a large disparity can also be 
expected between siblings with one similar gene mutation.  
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Other PID could manifest HLH without showing 
reduced cytotoxic cell degranulation. We have 
reported HLH patients with biotinidase deficiency 
(S.IV), IFN-γ receptor deficiency (S.X), and 
MAGT1 (S.XII). As such, patients with peculiar or 
chronic clinical presentation and family history 
should be followed up with sequencing even if CL 
function is normal. Research in the past years had 
provided answers to some patients but many 
unsolved cases remain. We have seen cases of 
clearly deficient degranulation or family history 
that have yet to be solved even after performing 
whole exome sequencing (not published) while 
apparently unrelated cases with neurological or 
gastrointestinal symptoms were found bearing 
primary defects (S.II, S.IX). The once clear 
domains of primary and secondary HLH are now 
becoming blurred with the discovery of various 
associated genes and novel mutations. Some 
previously monoallelic cases linked to late onset or 
atypical HLH have been found to carry non-coding 
mutations (Paper III,212,213).  
Cytotoxic lymphocytes play a crucial role in 
protecting the body. Failure of these cells to 
function normally due to an overwhelming 
intrusion on top of a primary defect leads to severe 
repercussions and even death. We have studied 
patients bearing such defects and found the NK 
degranulation assay sensitive in distinguishing 
patients bearing certain genetic defects of the 
degranulation pathway. This assay was further 
refined and was instrumental in detecting novel 
mutations, allowing us to diagnose more patients 
and better understand the biology of granule 
exocytosis. We have also established a parallel T 
cell degranulation assay and found it more 
sensitive when evaluated alongside the established 
NK assay. With continual development and 
expansion, we hope to expand the various assays 
to diagnose more primary diseases and improve 
assay stability. 
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5 CONCLUSIONS 
NK cells and CTL are together referred to as cytotoxic lymphocytes and play an important 
role in clearing infections and immunoregulation. This includes cytokine release and targeted 
cell killing via perforin granule exocytosis. The release of perforin granules is accompanied 
by the presence of surface CD107a, and termed degranulation. This assay can be used to 
evaluate both NK and T cells and represents a diagnostic assay to detect primary defects 
affecting cytotoxic lymphocyte function. The assay results can often be correlated to clinical 
data and has been reproduced in various diagnostic centers worldwide. 
 
Specific conclusions:  
Paper I 
• A detailed updated CD107a degranulation assay protocol is provided.  
• The intracellular staining of perforin is a reliable method of detecting defects and 
polymorphisms in the PRF1 gene. 
Paper II 
• A consensus K562-induced NK cell degranulation protocol was found to have an 
overall 96% sensitivity and 88% specificity for the diagnosis of genetic degranulation 
defects, namely in UNC13D, STX11, STXBP2, LYST, and RAB27A.  
• Results from the degranulation assay were not affected by immunosuppressive 
treatment and could still be performed after the initiation of the HLH-2004 protocol. 
• CTL blasts show low-level of degranulation after stimulation with CD3/CD28 beads 
and could possibly be used for evaluation of CTL function in patients where initial 
cell numbers are low. 
Paper III 
• The K562 induced NK cell degranulation assay was sensitive for the detection of 
defective degranulation in infants. 
• Two new non-coding mutations in UNC13D were described. The first is the c.118-
308C>T point mutation in a highly conserved region of intron 1, and the second a 
253kb inversion at the 3’ end of the gene. The inversion mutation was the first known 
description of an autosomal recessive human disease caused by an inversion. 
• Mutations in non-coding regions of UNC13D were found in 8 of 13 Swedish HLH 
infants between December 2005 and January 2011. Six of these eight were 
homozygous for the inversion mutation.  
• The inversion mutation was the most common UNC13D mutation as well as the most 
common genetic degranulation defect mutation in Sweden, with a possible founder 
effect originating from northern Scandinavia. 
• Patients bearing the c.118-308C>T intron 1 point mutation could be found throughout 
Europe with a similar haplotype and have spread over a large geographical area.  
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Paper IV 
• We described a novel point mutation in a highly conserved region of intron 1 of 
UNC13D, c.118-307G>A. 
• While the index patient quickly succumbed to illness, the older brother carrying a 
similar genotype and poorer cytotoxic cell function remaied asymptomatic, 
highlighting the large variability in clinical presentation and the challenges in drawing 
genotype-phenotype correlations.  
• Long transportation times led to lowered K562 induced NK degranulation in the 
samples shipped. The anti-CD16 and anti-CD3 induced degranulation assays were 
more robust and could still differentiate persons with genetic degranulation defects. 
Paper V 
• The loss of ORAI1 led to abrogated NK cell degranulation, cytotoxicity, as well as 
cytokine production. 
• Calcium mobilization is thus crucial for functional NK responses and ORAI1 is the 
SOCE mediator in NK cells. 
• Early LFA-1 signaling and granule polarization remained intact. Calcium influx is 
thus not required for initial signaling leading to adhesion and granule polarization.  
Paper VI 
• The CD3+CD8+CD57+ T cell compartment was shown to have high perforin and 
granzyme B content, and can be thus regarded as a bona fide cytotoxic T lymphocyte.  
• Stimulation with anti-CD3 antibody coated P815 cells induced rapid 
CD3+CD8+CD57+ T cell degranulation, cytokine production, and target cell killing.  
• This simple and rapid assay measured CD3+CD8+CD57+ T cell ex vivo activity 
without the need for any prior cell stimulation. 
• Patients having mutations in UNC13D, STX11, and STXBP2 were found to have a 
comparable defect in NK and CD3+CD8+CD57+ cell degranulation. IL-2 stimulation 
led to comparable levels of degranulation recovery in NK and CD3+CD8+CD57+ 
cells.  
• The T cell degranulation assay could possibly be used as a diagnostic assay for 
genetic degranulation defects.  
Paper VII 
• K562 stimulated NK cells displayed lower CD107a degranulation and a higher 
variance when compared to anti-CD16 NK cell and anti-CD3 T cell stimulation.  
• The downregulation of epigenetic factors FcεRγ and EAT-2 in NK cells corresponded 
to lowered K562 degranulation. 
• The anti-CD16 NK and anti-CD3 CD8+CD57+ degranulation assays were more 
accurate for the rapid functional diagnosis of genetic degranulation defects compared 
to the previous K562 induced NK degranulation standard. 
• We proposed running two degranulation assays simultaneously for confirming results 
and better overall specificity. 
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6 FUTURE DIRECTIONS 
The true impact of a genetic abnormality can only be determined using assays that reflect the 
function of that specific protein or pathway. Mutations can then be differentiated from 
polymorphisms. We have shown that direct staining of perforin as well as the magnitude of 
CD107a degranulation are assays that can separate out persons having defects in genes 
important for CL function. And while this thesis has focused on the clear black and white 
differences in resting state CL degranulation found in most primary HLH patients, the assay 
distinguishes shades of grey that we are currently exploring. 
While the current CD107a assay is good, CL degranulation still does not equate to actual 
target cell killing, which is the ‘gold standard’ for a cytotoxicity test. We hope to be able to 
incorporate a cell death marker into the degranulation assay as a cytotoxicity readout. 
Merging degranulation and cytotoxicity assays would allow for simultaneous detection of 
both effector cell and target cell response, strengthening the assay and saving on patient 
material. Specific effector to target ratios can be calculated for per cell killing levels similar 
to the chromium release assay. It could also be possible to directly evaluate CD57+ T cell 
killing. At the moment, because this population of cells constitutes a very small percentage of 
total lymphocytes, its killing effect is not apparent when performed on bulk PBMC.  
Using cell lines as targets produces significant variability when ran over prolonged periods 
(Paper VII). A possible solution would be to switch to a bead-based assay where specific 
antibodies are first captured on microbeads before added into PBMC giving more consistent 
results over time and improving assay accuracy. 
Concerning the mechanism by which CL gain function after cytokine stimulation, we would 
like to evaluate NK cells at resting and IL-2 stimulated states for loci with open DNA 
conformations.  It has been reported that the overexpression of Munc13-4, Rab27a, and Slp3 
in T cells from patients bearing LYST mutations led to recovery of function (217). Could 
similar compensatory mechanisms operate following cytokine stimulation, and why do only 
some defects show recovery and not others?  
Only one large population based functional evaluation of CL has been reported (218). NK 
cell cytotoxic function was examined in 3625 persons >40 yo with the aim of predicting 
cancer occurrences. Interestingly, the report did not mention any finding of defective NK cell 
cytotoxicity in the sample population. While the incidence of primary HLH in children has 
been studied in Sweden and estimated to be 1.2:1,000,000 (92), the many reports of late onset 
and atypical clinical presentation of primary HLH cases suggests that there could be a 
sizeable number of asymptomatic persons with defective CL function in the healthy 
population. As such, we would like to analyze and follow longitudinally a cross section of the 
Swedish population to examine how CL function and phenotype could be correlated to 
various disease occurrences in the long run. It is difficult to provide a global estimate of 
primary HLH rates as some mutations are stratified by ethnicity and geography. Confound 
that with increasing human mobility, number of interracial families, and the complexity of 
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posttranslational modifications that are not gene encoded, one quickly realizes that such a 
study could raise more questions than answers. Still, this important work should be 
performed, and by including clinical, genetic, epigenetic, and functional results, we hope the 
data would allow us to better understand the importance of CL function in human disease.  
A registry study found an increased rate of malignancy in first-degree female relatives of 
primary Swedish HLH patients who are genetic carriers (S.XIV). However, evaluation of CL 
activity did not reveal any differences between carriers and healthy controls. This could be 
due to the small sample size, a lack of sensitivity in assays ran, or an organ specific NK 
functional deficiency, as cervical carcinoma was the most frequent cancer reported. NK cells 
in the periphery vary from those in organs and we are lacking specific knowledge on how NK 
cells with primary defects in degranulation are affected in their function in the various organs. 
Clearly, more work is required to explain this observation of increased cancer rates. 
At the beginning of my PhD, I have hoped that my work would make a difference in the lives 
of the many very ill patients we evaluate. We have progressed steadily and have now a very 
rapid and robust group of assays for the diagnosis of genetic diseases predisposing to 
defective CL degranulation. While this has been evaluated for a few different genes, the 
booming PID field mandates tremendous effort to be placed in the development of new and 
better diagnostic assays. As a case in point, one survey found 19 new PID genes published in 
a year (130). Lately, we have also found with more regularity primary HLH patients with 
atypical presentations and more PID patients presenting with clinical HLH. Because it is 
impossible to run every single assay on every patient, we look forward to the near future 
where rapid whole exome/genome sequencing will play a major role. An overnight sequencer 
will generate a list of possible candidate genes, directing us to perform specific validation 
assays when we come in to the lab the next morning. 
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8 LAYMAN’S SUMMARY 
 
"I'm not trying to be mysterious about it,  
it's just that what I do is tough to explain." 
MacGyver (Season 6, Jerico Games) 
This section aims to distill in simple English the gist of this thesis, what this is all about, and 
what all the results mean. 
All living humans (should) have blood which is mainly made up of red blood cells that 
transport oxygen, platelets that help wound clotting, and white blood cells (WBC), the soldier 
cell that keeps us healthy by killing off ‘bad’ cells. ‘Bad’ cells could mean our own cells that 
have been compromized by bacteria/viruses, cells growing out of control: tumors, or other 
white blood cells that have done their job and should be removed. So WBC clear infections 
and regulate the body’s defense system. 
This thesis looks at a subset of WBC termed cytotoxic cells. Cytotoxic means being able to 
directly kill (toxic) other cells (cyto). There are two major types of cytotoxic cells: natural 
killer (NK) cells and cytotoxic T lymphocytes (CTL). 
NK cells make and store little packets of poison, then roam around the body looking for a bad 
cell. When it finds one, the NK cell grabs on to the bad cell and releases poison at the precise 
area where the link is formed, killing it. The NK cell then breaks the link and goes away 
looking for another target. The mechanism of exactly how these NK cells work is only 
roughly known. Doubtless, should this army of specialized killer cells fail, one will fall sick 
quite easily.  
A person’s DNA originates from his or her biological parents, i.e. one gets two copies 
(alleles) of the same gene, a copy from each parent, for every gene (except those on the X and 
Y chromosomes, girls have XX, boys have XY). If the father passed down a defective gene, 
but the maternal one is normal, most times the child would be normal because it’s enough to 
have one functional copy. However, if both copies are defective, the defect will be noticeable. 
Some unfortunate persons are born with two defective copies of genes required in the NK cell 
killing process and thus carry malfunctioning killer cells. These defective cells lead to an 
increased susceptibility to infections and cancer. The current treatment for this is bone 
marrow transplantation (removing all blood cells and receiving a transplant from a healthy 
donor). This is a serious decision and is the same treatment for leukemia. As such, there is a 
need to quickly and accurately diagnose patients to ensure that proper treatment is given. 
The laboratory receives blood samples from suspected patients around the world. Functional 
tests are run on them which entails mixing in certain cancer cells together with white blood 
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cells to determine if natural killer (NK) cells are able to kill those cancer cells. Paper I is a 
protocol on how to run this test.  
If the patient’s cytotoxic cells did not respond by killing the added cancer cells, there is a high 
chance the poor killing is caused by an error at the DNA/gene level; this is termed ‘primary’ 
disease. If the cells look and respond normally, it might be a one-off overreaction of the body, 
and termed ‘secondary’ disease. Or, the patient might have a different primary disease and 
the assay does not detect it. DNA from patients with poor killing potential were then 
sequenced, which basically means to read their DNA at particular locations to see if it reads 
the same as in healthy persons. If there is a significant mistake, it could be the cause of 
disease.  
Compiling the sequencing and cancer killing test results from four European laboratories, we 
collected 120 primary cases. From that, it was found that poor natural killer (NK) cancer-
response killing result can be used as a predictor of patients having a DNA error in one of the 
genes important for cytotoxic cell function (Paper II). This test has a 96% sensitivity and 
88% specificity. That means if we test 100 patients that truly have defects in genes linked to 
cytotoxic-cell tumor-responding potential, our test would pick out 96 of them (true positives). 
Conversely, if we tested 100 healthy persons with no genetic defect, our test will say 88 of 
them are normal (true negatives). 
What puzzled us was some patients having poor tumor killing did not show any errors in the 
regular suspect genes. Instead, after much testing, errors were found in the ‘junk’ (intronic) 
parts of the gene (Paper III). A gene is a region of DNA that usually contains codes for one 
product (protein). Some DNA sections are code for parts that end up in the product (exon) 
while some are code that don’t get into the final product (intron). Thus, some regard intronic 
regions as ‘junk’ DNA. However we found that in some patients, errors in a ‘junk’ region of 
the gene UNC13D led to defective NK function. We did not find this error initially as regular 
DNA sequencing does not include ‘junk’ regions (like reading a magazine and skipping all 
the ads in between). In Paper IV, we found another intronic mutation neighboring the one 
found in Paper III, highlighting the importance of this particular section of ‘junk’ DNA. We 
follow up on this in supplementary paper S.VIII and found this particular ‘junk’ region to be 
important in unwinding DNA, without which, the DNA remained tightly coiled and cannot be 
employed in protein production. 
Paper V. Metal ions (in salt form) play important roles in cell function. We studied a patient 
having a defective protein (ORAI1) crucial for calcium transport into the cell. The movement 
of salt into cells leads to concentration changes, which triggers cells to perform certain 
actions. When ORAI1 is defective, we found that calcium cannot get into NK cells when it 
recognizes a cancer cell, which should normally happen. This leads to the NK cell not being 
able to mount a killing response or release signals to warn other nearby immune cells. This 
proves that NK cells require a flux of salt to function and ORAI1 is the channel specifically 
mediating NK cell activation.  
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All this while, only NK cells were studied. The test for CTLs at that point had shortcomings 
and so we decided to develop a new assay. NK cells have poison packets already in them 
from the start but CTLs are traditionally thought to be ‘slower’, having to be activated a few 
days before they can kill. A test that could be run immediately with fresh blood cells is 
preferred because sometimes the patients/doctors can’t wait a few days.  
CTLs are a mixed bunch; so those that had ready poison packets in them were singled out. By 
chance, these CTLs had the marker CD57 on the outside surface. When a compound to 
activate CTLs was added in, CTLs expressing CD57 were found to kill cancer cells (Paper 
VI). Better yet, patients with a defect in NK tumor killing were tested and found to be also 
defective in CTL cell killing, i.e. the underlying genetic defect affects both NK and CTL. 
To evaluate this CTL test, we compared it with the original NK test (Paper VII). This meant 
repeating Paper II with an additional CTL degranulation test. Collecting approximately a 
hundred patients over three years, the CTL assay was found to be better than the NK test. The 
sensitivity and specificity for the CTL assay is 97% and 95% respectively. So the CTL test is 
more accurate compared to the first NK assay in predicting which persons have a true genetic 
defect. However, we suggested that both the NK and CTL test be run simultaneously on all 
patients just in case one fails as well as a confirmatory test. 
In a nutshell, if you skipped all the way to this paragraph, what I accomplished during my 
doctoral studies was to create, improve, and evaluate diagnostic tests for a rare inherited 
syndrome (familial hemophagocytic lymphohistiocytosis), which led me (together with a 
whole team of scientists and doctors) to a better understanding of the importance and the 
function of cytotoxic white blood cells: what makes them tick and why they sometimes fail to 
function 
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